Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Jazz Pharma Plc (NQ: JAZZ )

117.59 -4.06 (-3.34%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 18, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Jazz Pharma Plc

< Previous 1 2 3 4 5 6 7 8 9
...
12 13 Next >
Expert Ratings for Jazz Pharmaceuticals
Via Benzinga
3 Cheap Growth Stocks That Are Too Good to Pass Up
These top bargain growth stocks are all priced under $10 a share and offer real upside potential for investors. 
Via InvestorPlace
Big Developments in Cancer Treatments set for Upcoming ASCO 2023 Annual Meeting in June
EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:JAZZ),(NASDAQ:GERN),(NASDAQ:INAB),(NASDAQ:VCYT) EQNX::TICKER_END 
Via FinancialNewsMedia
Exposures Product Safety
FDA Presents Potential Framework For CBD, From Edibles To Delta-8, Reaffirms Congress Is In Charge
The U.S. Food and Drug Administration has not given up on regulating CBD and hemp-derived products in a way that would be safe for consumers and producers. 
Via Benzinga
Ford To Rally Around 33%? Here Are 10 Other Analyst Forecasts For Tuesday
Keybanc boosted the price target for Broadcom Inc. (NASDAQ: AVGO) from $720 to $820. Keybanc analyst John Vinh maintained the stock with an Overweight rating. Broadcom shares rose 11.5% to close at... 
Via Benzinga
Where Jazz Pharmaceuticals Stands With Analysts
Via Benzinga
Recap: Jazz Pharmaceuticals Q1 Earnings
Via Benzinga
Jazz Pharmaceuticals Analysis Reveals THC And CBD Therapy Alleviates MS Spasticity
Treatment with the cannabis-based oral spray Nabiximols has been found to significantly relieve spasticity, a common symptom of multiple sclerosis (MS), according to a new analysis of two MS clinical... 
Via Benzinga
World-First Clinical Trial Using Cannabis-Based Drug To Treat Deadly Brain Tumors Recruits First Patients
Can a cannabis-based medicine help treat aggressive brain tumors? Scientists in the UK are getting closer to answering that question. Ongoing lab research is about to become real-world as the project... 
Via Benzinga
Jazz Pharma Q1 FY23 Revenue Grows 10% YoY, What About Net Income?
Jazz Pharmaceuticals plc (NASDAQ: JAZZ) released financial results for the first quarter of 2023, revealing revenue of $892.8 million, an increase of 10% compared to $813.7 million in Q1 2022. 
Via Benzinga
Axsome's New Drug Is Scoring a Win. Is the Stock a Buy?
The biotech's share price more than doubled during last year's bear market. 
Via The Motley Fool
GlycoMimetics: A Breakthrough In Hematopoietic Stem Cell Transplantation
Blood cancers such as AML, MM, and MDS affect a terrible toll on patients and their loved ones. Glycomimetics may be such a company that can offer patients suffering from various blood cancers hope... 
Via Talk Markets
Why Avadel Pharma Shares Are Gaining Today
Via Benzinga
The Latest Analyst Ratings for Jazz Pharmaceuticals
Via Benzinga
Pressure BioScience's Pressure-Based Tech Is Ready To Spur Innovation And Growth In A Life Sciences Sector In Flux
Often considered recession-proof, the life sciences sector faced a surprising amount of uncertainty over the past few years with up to 80% of companies saying they’ve been negatively impacted by the... 
Via Benzinga
Why Shares of Avadel Soared This Week
The company got its first FDA approval. 
Via The Motley Fool
If You Invested $5,000 in Axsome Therapeutics 5 Years Ago, Here's How Much You Would Have Now
Axsome's new products have blockbuster potential. 
Via The Motley Fool
The Top Healthcare Stocks to Buy With $100
A small investment now may bring big results over time. 
Via The Motley Fool
The Global Cannabis Pharmaceuticals Market Size Is Expected To Surpass $125 Billion by 2028
EQNX::TICKER_START (OTCQX:TCNNF),(OTCQX:CURLF),(NASDAQ:TLRY),(NASDAQ:JAZZ) EQNX::TICKER_END 
Via FinancialNewsMedia
Topics Cannabis
Exposures COVID-19 Cannabis
2 Top Biotech Stocks to Buy in April
Right now you can pick up these stocks on the dip. 
Via The Motley Fool
The 3 Best Growth Stocks to Buy in the Biotech Sector
These three biotech growth stocks are brimming with potential and could offer massive upside for patient investors. 
Via InvestorPlace
Is Big Pharma Coming For Your Cannabis Business?
Cannabis stocks have struggled in the market in recent years as the industry push to gain ground on the regulatory front hasn't progressed as quickly as investors had hoped. Yet beverage companies... 
Via Benzinga
My Top Cannabis Stock to Buy in 2023 and Hold For 10 Years
The cannabis sector has been disappointing in recent years, but this company stands out. 
Via The Motley Fool
Medical Marijuana Milestone In The UK: Celadon Pharmaceuticals Becomes First Company With License To Sell In Britain
Celadon Pharmaceuticals has become the first UK-based medical cannabis manufacturer to be granted a Home Office license to sell its products in the UK.  
Via Benzinga
Silicon Valley Bank Failure Is Just The Tip Of Financial Iceberg, Could Affect Unexpected Industries
Last week the US economy got clobbered by the biggest banking collapse since 2008 when the parent of Silicon Valley Bank, SVB Financial Group (NASDAQ: SIVB) failed to raise enough capital to continue. 
Via Benzinga
Zymeworks Offers Hope for More than Just Long-Term Investors
Zymeworks stock is up nearly 5% since reporting earnings and a rally that has put ZYME stock over 25% in the last 12 months and could send the stock higher 
Via MarketBeat
With Access To $20 Million In Financing, 1606 Corp Is Eyeing CBD Business Acquisitions As It Embarks On An Aggressive Growth Path
The global CBD market is on an upward trajectory, and there are no indications that the growth could be slowing down anytime soon. The market was valued at $5.18 billion in 2021 and is expected to... 
Via Benzinga
Pharma Mafia Wants To Conquer Cannabis: Can You Patent A Plant? Jazz Is Trying
The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) recently published collected data on CBD safety, placing the information under its Yellow Card alert system, which lists various... 
Via Benzinga
Why Cannabis Is Recession-Resistant & Turning Challenges Into Opportunities, Industry Expert Explains
It is safe to say that the cannabis industry would not have progressed as much as it has if it were not for the people who believed in it. Cannabis advocates, lobbyists, growers, operators, consumers... 
Via Benzinga
Jazz Q4 2022 Revenue Grows 8% To $972M, Provides Outlook
Jazz Pharmaceuticals plc (NASDAQ: JAZZ) Q4 2022 revenue was $972.12 million an 8% increase compared to 896.73 million in Q4 2021. Financial Highlights 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
12 13 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.